EBMT 2023 | Comparing BMT and CAR-T therapy: learnings for patient care and management

Natacha Bolaños, Lymphoma Coalition Europe, Madrid, Spain, comments on the intersection of bone marrow transplantation (BMT) and CAR-T therapy. While both treatments have similarities in patient trajectory, there are differences in toxicities experienced, with BMT having a higher risk of graft-versus-host disease (GvHD), and CAR-T therapy having more neurotoxicity and cytokine release syndrome (CRS). However, the learnings from BMT are also helping to improve the clinical practice of CAR-T therapy. Furthermore, CAR-T therapy has expanded treatment options for patients who may not meet the criteria for BMT, and there are similarities in the problems experienced by patients who have received BMT and CAR-T. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.